Manu Chaudhary
YOU?
Author Swipe
View article: Bioequivalence of a biosimilar enoxaparin (<scp>Cloti‐Xa™</scp>) and its innovator (Clexane<sup>®</sup>): A <scp>single‐dose</scp>, randomized, <scp>double‐blind</scp>, <scp>two‐period</scp>, <scp>two‐treatment</scp>, <scp>two‐sequence</scp>, crossover, balanced study in healthy human subjects
Bioequivalence of a biosimilar enoxaparin (<span>Cloti‐Xa™</span>) and its innovator (Clexane<sup>®</sup>): A <span>single‐dose</span>, randomized, <span>double‐blind</span>, <span>two‐period</span>, <span>two‐treatment</span>, <span>two‐sequence</span>, crossover, balanced study in healthy human subjects Open
Currently, several biosimilars of low‐molecular‐weight heparins (LMWHs) with differing potencies are being developed and marketed globally. Thus, it is important that the potency of each biosimilar LMWH be compared with its innovator's mol…
View article: A study of the effect of yoga on C-reactive protein, lipid profile and insulin resistance in obese patients
A study of the effect of yoga on C-reactive protein, lipid profile and insulin resistance in obese patients Open
Background: Obesity is defined as a state of excess adipose tissue mass. In the last decade, there has been an alarming prevalence of obesity in the developed and developing countries like India. While modern medicine has so far been unabl…
View article: P06 Pharmacokinetics and renal accumulation of VRP-034
P06 Pharmacokinetics and renal accumulation of VRP-034 Open
Background Nephrotoxicity is a dose-limiting factor for polymyxin B (PMB), a last-line therapy for MDR Gram-negative bacterial infections. The majority of the filtered PMB undergoes extensive tubular reabsorption leading to significant acc…
View article: Polymyxin B-Induced Kidney Injury Assessment of a Novel Formulation of Polymyxin B (VRP-034) in Rats
Polymyxin B-Induced Kidney Injury Assessment of a Novel Formulation of Polymyxin B (VRP-034) in Rats Open
Despite the crucial role of Polymyxin-B in treating life-threatening gram-negative infections, its clinical utility is limited due to the risk of acute kidney injury. In response, a novel formulation of polymyxin-B is being developed to mi…
View article: Ultrasonic investigation of molecular interactions in aqueous alkaline solution of mono azo dye metanil yellow and hexacyanoferrate(III) ions
Ultrasonic investigation of molecular interactions in aqueous alkaline solution of mono azo dye metanil yellow and hexacyanoferrate(III) ions Open
In order to investigate the nature of molecular interaction in the reaction mixture of metanil yellow with hexacyanoferrate (III) ions in basic medium, ultrasonic velocity was measured over wide ranges of concentrations.The different acous…
View article: 1974. Ceftriaxone-Sulbactam-EDTA vs. Meropenem in PLEA (a Phase 3, Randomized, Double-Blind Trial): Outcomes by Baseline MIC in Adults With Complicated Urinary Tract Infections or Acute Pyelonephritis
1974. Ceftriaxone-Sulbactam-EDTA vs. Meropenem in PLEA (a Phase 3, Randomized, Double-Blind Trial): Outcomes by Baseline MIC in Adults With Complicated Urinary Tract Infections or Acute Pyelonephritis Open
BACKGROUND: Ceftriaxone–sulbactam–disodium EDTA (CSE) is being developed for Gram-negative infections caused by multidrug-resistant (MDR) bacteria. PLEA was a Phase 3, double-blind, multicenter, randomized study of CSE vs. meropenem (MR) f…
View article: 1959. Ceftriaxone-Sulbactam-EDTA (CSE) vs. Meropenem (MR) in PLEA (a Phase 3, Randomized, Double-Blind Trial): Outcomes in Patients Infected With Ceftriaxone Non-Susceptible, Extended-Spectrum β-Lactamase and Multi-Drug-resistant Pathogens at Baseline
1959. Ceftriaxone-Sulbactam-EDTA (CSE) vs. Meropenem (MR) in PLEA (a Phase 3, Randomized, Double-Blind Trial): Outcomes in Patients Infected With Ceftriaxone Non-Susceptible, Extended-Spectrum β-Lactamase and Multi-Drug-resistant Pathogens at Baseline Open
BACKGROUND: CSE, a novel combination of Ceftriaxone, Sulbactam and Disodium EDTA (Class 1 Antibiotic Resistance Breaker), is being developed for the treatment of patients with serious Gram-negative infections and has completed a Phase-3 cl…
View article: 1373. Activity of Ceftriaxone–Sulbactam–EDTA Against Multi-Drug-resistant A. baumannii, P. aeruginosa and Enterobacteriaceae Isolates (WHO Critical Priority Pathogens) Collected from Various Hospitals in India
1373. Activity of Ceftriaxone–Sulbactam–EDTA Against Multi-Drug-resistant A. baumannii, P. aeruginosa and Enterobacteriaceae Isolates (WHO Critical Priority Pathogens) Collected from Various Hospitals in India Open
Background Ceftriaxone–Sulbactam–EDTA (CSE) is the first cephalosporin–β-lactamase inhibitor combination with an antibiotic resistance breaker–disodium edetate, recently evaluated in a Phase 3 clinical trial for treatment of adults with co…
View article: 1984. Ceftriaxone-Sulbactam-EDTA vs. Meropenem: Analysis of Failed Patients With Assessment of MIC Increases and Changes in Genotypic Profile in PLEA (a Phase 3, Randomized, Double-Blind Clinical Trial in Adults With Complicated Urinary Tract Infections or Acute Pyelonephritis)
1984. Ceftriaxone-Sulbactam-EDTA vs. Meropenem: Analysis of Failed Patients With Assessment of MIC Increases and Changes in Genotypic Profile in PLEA (a Phase 3, Randomized, Double-Blind Clinical Trial in Adults With Complicated Urinary Tract Infections or Acute Pyelonephritis) Open
BACKGROUND: Ceftriaxone–sulbactam–EDTA (CSE) is a novel combination being developed to treat serious infections caused by Gram-negative bacteria. In vitro molecular biology studies have shown that the addition of EDTA in the combination he…
View article: Comparative efficacy and safety analysis of CSE-1034: An open labeled phase III study in community acquired pneumonia
Comparative efficacy and safety analysis of CSE-1034: An open labeled phase III study in community acquired pneumonia Open
Overall assessment of clinical cure rate, microbiological eradication rate and safety assessment in this study has shown that CSE-1034 is an effective and safe option for the treatment of CAP patients of PORT risk III-IV. Moreover, the sup…
View article: CSE-1034 versus ceftriaxone: Efficacy and safety analysis from a randomized, open-labeled phase III study in complicated urinary tract infections
CSE-1034 versus ceftriaxone: Efficacy and safety analysis from a randomized, open-labeled phase III study in complicated urinary tract infections Open
CSE-1034 3 g every 24 h showed a high favorable clinical and bacteriological response, and 95% CI around the treatment difference prove the superiority of CSE-1034 vs. Ceftriaxone for the treatment of cUTI. Therefore, CSE-1034 provides an …
View article: Advancing in the Direction of Right Solutions: Treating Multidrug-Resistant Pneumonia
Advancing in the Direction of Right Solutions: Treating Multidrug-Resistant Pneumonia Open
Worldwide, antibiotic resistance is a major contemporary public health threat due to rapid emergence of resistant bacteria and endangering the efficacy of antibiotics. There are significant number of reports on clinical failure of β-lactam…
View article: Safety and efficacy of a novel drug elores (ceftriaxone + sulbactam + disodium edetate) in the management of multi-drug resistant bacterial infections in tertiary care centers: a post-marketing surveillance study
Safety and efficacy of a novel drug elores (ceftriaxone + sulbactam + disodium edetate) in the management of multi-drug resistant bacterial infections in tertiary care centers: a post-marketing surveillance study Open
In this post-marketing surveillance study, CSE-1034 was found to be an effective and safe option against Pip tazo and meropenem in management of patients with multi-drug resistant (MDR) bacterial infections under routine ward settings.
View article: India's Foreign Policy and BRICS
India's Foreign Policy and BRICS Open
View article: Dose optimization of ceftriaxone-vancomycin combination using fractional inhibitory concentration kinetics in resistant bacteria
Dose optimization of ceftriaxone-vancomycin combination using fractional inhibitory concentration kinetics in resistant bacteria Open
The notorious Staphylococcus aureus resistant strains with ever changing resistance patterns have limited treatment options and have led to substantial number of deaths. Almost dried antibiotic pipeline has led us to look into combinations…
View article: DOSE OPTIMIZATION OF CEFTRIAXONE-SULBACTAM COMBINATION IN ADULTS USING IN VITRO SYSTEMS, PK/PD MODELING AND STOCHASTIC SIMULATIONS APPROACHES
DOSE OPTIMIZATION OF CEFTRIAXONE-SULBACTAM COMBINATION IN ADULTS USING IN VITRO SYSTEMS, PK/PD MODELING AND STOCHASTIC SIMULATIONS APPROACHES Open
Objective: To optimize the dosage regimen of fixed-dose combination (FDC) of ceftriaxone/sulbactam (2/1 w/w) using in vitro system, pharmacokinetic/pharmacodynamic (PK/PD) modeling and Monte-Carlo simulations (MCS). Methods: One comp…
View article: Population Pharmacokinetics of Fixed Dose Combination of Ceftriaxone and Sulbactam in Healthy and Infected Subjects
Population Pharmacokinetics of Fixed Dose Combination of Ceftriaxone and Sulbactam in Healthy and Infected Subjects Open
View article: COMPARATIVE IN VITRO ACTIVITY OF SUPIME AGAINST GRAM NEGATIVE CLINICAL ISOLATES
COMPARATIVE IN VITRO ACTIVITY OF SUPIME AGAINST GRAM NEGATIVE CLINICAL ISOLATES Open
Objective: Present investigation was undertaken to know the prevalence of extended spectrum beta-lactamases (ESBLs) among the collected isolates and to analyse the antibiotic susceptibility patterns of cefepime/sulbactam, cefepime/tazobac…
View article: EVALUATION OF EZENUS IN AN EXPERIMENTAL MODEL OF DIET-INDUCED ALCOHOLIC AND NON-ALCOHOLIC FATTY LIVER CONDITION IN RATS
EVALUATION OF EZENUS IN AN EXPERIMENTAL MODEL OF DIET-INDUCED ALCOHOLIC AND NON-ALCOHOLIC FATTY LIVER CONDITION IN RATS Open
Objective: Alcoholic and non-alcoholic fatty liver disease are found to affect more than 10% of the general population. Fatty liver condition in humans is directly correlated with psychosocial stress. Herbal formulations for the managemen…
View article: Comparative in Vitro Activity of Zydotum against Gram Negative and Gram Positive Clinical Isolates
Comparative in Vitro Activity of Zydotum against Gram Negative and Gram Positive Clinical Isolates Open
View article: Microbial Surveillance and Susceptibility of Gram-Positive Bacteria to Antibiotic Drugs
Microbial Surveillance and Susceptibility of Gram-Positive Bacteria to Antibiotic Drugs Open
Incidence of antimicrobial resistance among Gram-positive organisms has been increasing steadily to most of the currently available anti bacterials, making it extremely difficult to treat infections. Purpose of this study was to assess the…
View article: Microbial Surveillance and Susceptibility of Gram-Positive Bacteria to Antibiotic Drugs
Microbial Surveillance and Susceptibility of Gram-Positive Bacteria to Antibiotic Drugs Open
View article: Comparative in Vitro Activity of Zydotum against Gram Negative and Gram Positive Clinical Isolates
Comparative in Vitro Activity of Zydotum against Gram Negative and Gram Positive Clinical Isolates Open